Ipsen CEO David Loew is elected to EFPIA leadership; joins industry partners to warn of impact of EU pharma legislation - Global
Press Releases - Ipsen UK
Ipsen and Medetia join forces to accelerate early research in rare disease - Global
Ipsen: Patients Living with Spasticity Want Long-lasting Symptom Relief | Business Wire
Gebrüder Weiss takes over Ipsen Logistics' Air & Sea business | DC Velocity
Ipsen (@IpsenGroup) / X
Press Releases - Ipsen UK
Ipsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV Discovery | Liberi Group
Mayoly Spindler completed the acquisition of Ipsen's CHC branch - MAYOLY SPINDLER laboratoire indépendant français
Ipsen NHS Study Published - IFOPA - International Fibrodysplasia Ossificans Progressiva Association
Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
Press Releases - Ipsen UK
IPSEN: Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy | FDA Reporter
Press releases
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3 | Business Wire
Ipsen media library
Ipsen Goes All In on Neuro with $1 Billion+ Deal For Exicure's Oligonucleotides | BioSpace
Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts | Financial Post
Press Releases - Ipsen UK
Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Ipsen is officially recognized as a great place to work worldwide - Global
